Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US.
COVID-19
SARS-CoV-2
electronic health records
inflammatory response
mortality rate
oxidative stress
statins
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
12
2020
accepted:
06
01
2021
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
The severe respiratory illness due to SARS-CoV-2, the virus responsible for coronavirus disease 2019 (COVID-19), is triggered by an intense pro-inflammatory host response. Statins, prescribed primarily for lipid reduction, are known to have anti-inflammatory and immunomodulatory properties and have been associated with a reduced mortality rate among COVID-19 patients taking statins as reported in two recent retrospective studies. However, a meta-analysis that included nine studies showed that statin use did not improve in-hospital outcomes of those with COVID-19. In addition, concerns regarding the use of statins and an increase in COVID-19 infections have been raised, as statins may increase the expression of angiotensin-converting enzyme 2 (ACE2), the primary receptor for the SARS-CoV-2 virus. Our goal was to investigate the effect of statins in COVID-19 patients in a large, diverse patient population across the United States containing nearly 120,000 patients diagnosed with COVID-19. We used propensity score matching of demographics, comorbidities, and medication indication to compare statin-treated patients (
Identifiants
pubmed: 33614688
doi: 10.3389/fmed.2021.639804
pmc: PMC7887302
doi:
Types de publication
Journal Article
Langues
eng
Pagination
639804Informations de copyright
Copyright © 2021 Marić, Oskotsky, Kosti, Le, Wong, Shaw, Sirota and Stevenson.
Déclaration de conflit d'intérêts
MS is a scientific advisor at twoXAR. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Metab. 2020 Aug 4;32(2):176-187.e4
pubmed: 32592657
Chest. 2007 Apr;131(4):1006-12
pubmed: 17426203
Diabetes Res Clin Pract. 2020 Jun;164:108228
pubmed: 32446801
Biochem Biophys Res Commun. 2014 Mar 28;446(1):292-7
pubmed: 24582748
Immunology. 2018 May;154(1):69-75
pubmed: 29392731
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1225-1229
pubmed: 32683320
Br J Pharmacol. 2020 Nov;177(21):4873-4886
pubmed: 32562276
Antioxidants (Basel). 2020 Jun 19;9(6):
pubmed: 32575554
Antioxidants (Basel). 2020 Jul 18;9(7):
pubmed: 32708430
Blood Rev. 2020 Aug 24;:100745
pubmed: 32868115
Placenta. 2019 Jan;75:1-8
pubmed: 30712660
Free Radic Biol Med. 2020 Dec;161:263-271
pubmed: 33091573
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Biochem Biophys Res Commun. 2006 May 12;343(3):738-44
pubmed: 16563347
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
Diabetes Metab. 2020 Oct 19;:101202
pubmed: 33091555
J Am Med Dir Assoc. 2020 Jul;21(7):909-914.e2
pubmed: 32674818
Cell Metab. 2020 Aug 4;32(2):145-147
pubmed: 32755604
Curr Pharm Des. 2012;18(11):1519-30
pubmed: 22364136
Biomed Res Int. 2014;2014:872370
pubmed: 25478576
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):258-259
pubmed: 32347925
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
J Clin Invest. 1999 Jan;103(1):129-35
pubmed: 9884342
Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):229-36
pubmed: 25359861
Arch Med Sci. 2020 Apr 25;16(3):490-496
pubmed: 32399094
Antiviral Res. 2013 Sep;99(3):417-35
pubmed: 23831494
Toxicol Rep. 2020;7:1170-1171
pubmed: 32904637
Can J Physiol Pharmacol. 2007 Aug;85(8):800-10
pubmed: 17901890
mBio. 2020 Mar 20;11(2):
pubmed: 32198163
PLoS One. 2016 Feb 19;11(2):e0149288
pubmed: 26894432
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):410-411
pubmed: 32529218
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1613-1615
pubmed: 32882643